Abstract:Autoreactive B cells are characterized by their ability to secrete autoantibodies directed against self-peptides. During the last decade, it has become increasingly apparent that B lymphocytes not only produce autoantibodies but also exert important regulatory roles independent of their function as antibody-producing cells. This is especially relevant in the context of autoimmunity, because autoreactive B cells have been shown to possess the ability to activate pathogenic T cells, to produce pro-inflammatory cytokines, and to promote the formation of tertiary lymphoid tissue in target organs. The production of monoclonal antibodies against B-cell-surface molecules has facilitated the characterization of several distinct B lymphocyte subsets. These cell-surface molecules have not only served as useful cell differentiation markers but have also helped to unravel the important biological functions of these cells. Some of these molecules, all of which are expressed on the cell surface, have proven to be effective therapeutic targets. In both animal models and in clinical assays, the efficient elimination of B lymphocytes has been shown to be useful in the treatment of rheumatoid arthritis and other autoimmune diseases. The treatment of most rheumatic autoimmune diseases relies mainly on the use of cytotoxic immunosuppressants and corticosteroids. Although this has resulted in improved disease survival, patients may nonetheless suffer severe adverse events and, in some cases, their relapse rate remains high. The increasing need for safer and more effective drugs along with burgeoning new insights into the pathogenesis of these disorders has fueled interest in biological agents; clinical trials involving the B-cell depletion agent rituximab have been especially promising. This article reviews the current knowledge of B-cell biology and pathogenesis as well as the modern therapeutic approaches for rheumatic autoimmune diseases focusing in particular on the targeting of B-cell-specific surface molecules and on the blocking of B-cell activation and survival.

CD20+ B Cell Depletion in Systemic Autoimmune Diseases: Common Mechanism of Inhibition or Disease-Specific Effect on Humoral Immunity?

B-Cell Depletion and Repopulation in Autoimmune Diseases

B cell depletion therapy in autoimmune diseases.

Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?

B-cell depletion in autoimmune diseases

The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases

Translational Mini‐Review Series on B Cell‐Directed Therapies: The pathogenic role of B cells in autoantibody‐associated autoimmune diseases – lessons from B cell‐depletion therapy

B cell depletion in autoimmune rheumatic diseases

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Targeting B Cells and Plasma Cells in Autoimmune Diseases

B Cell Modulation Strategies in Autoimmune Diseases: New Concepts

Cutting-edge approaches to B-cell depletion in autoimmune diseases

Long-Lived Plasma Cells in Autoimmunity: Lessons from B-Cell Depleting Therapy

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases

B cell-targeted therapies in autoimmunity: rationale and progress

Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune Diseases

[Rituximab and autoimmune disorders therapy]

B cell depletion in autoimmune diabetes: insights from murine models

Rituximab in autoimmune hematologic diseases: not just a matter of B cells